Journal
CELL CYCLE
Volume 9, Issue 24, Pages 4788-4794Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.9.24.14360
Keywords
cell senescence; mTOR; rapamycin; target of rapamycin; aging; diseases
Categories
Ask authors/readers for more resources
Although we do not know everything about aging, we now know enough to start its pharmacologic suppression using clinically approved drugs. Aging turns out to be driven by sensing-signaling pathways (such as the mTOR pathway). Given that some inhibitors of the mTOR pathway are already in clinical use, there is a unique opportunity to suppress aging, while treating and preventing diseases. By itself this will answer some burning questions in gerontology. Here I discuss a proposal, starting from retrospective clinical studies to animal and cellular models to drug screens in order to develop non-toxic and effective schedules and drug combinations for extending healthy life spans in our lifetime.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available